Seres Therapeutics Inc (MCRB)

Currency in USD
14.2100
-1.0800(-7.06%)
Real-time Data·
After Hours
14.21000.0000(0.00%)
·
MCRB Scorecard
Full Analysis
Quickly burning through cash
MCRB is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
14.090015.5477
52 wk Range
6.530026.4000
Key Statistics
Prev. Close
15.29
Open
15.05
Day's Range
14.09-15.5477
52 wk Range
6.53-26.4
Volume
79.19K
Average Volume (3m)
121.3K
1-Year Change
-13.13%
Book Value / Share
3.77
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MCRB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
13.3333
Downside
-6.17%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Seres Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Seres Therapeutics Inc Company Profile

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. Its other pipeline programs include SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease; and SER-287 and SER-301, which are in clinical trials for the treatment of mild-to-moderate ulcerative colitis. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Seres Therapeutics Inc Earnings Call Summary for Q2/2025

  • Q2 2025 EPS at -$2.27, missing -$0.09 forecast; net loss $19.9M, improved from $26.2M in Q2 2024
  • SER-155 program advancing, showing promise in reducing bloodstream infections; Phase II study planned with 248 participants
  • Stock down 1.89% to $14.01 in premarket; company seeking capital through partnerships and potential mergers
  • Cash reserves at $45.4M as of June 30, 2025; company aims to extend cash runway into 2026
  • Analyst targets range $6-$20 per share; EPS forecast remains negative at -$4.41 for FY2025
Last Updated: 06/08/2025, 14:40
Read Full Transcript

Compare MCRB to Peers and Sector

Metrics to compare
MCRB
Peers
Sector
Relationship
P/E Ratio
−2.4x−3.4x−0.5x
PEG Ratio
−0.02−0.010.00
Price/Book
3.8x2.2x2.6x
Price / LTM Sales
-9.7x3.3x
Upside (Analyst Target)
−1.9%200.5%43.4%
Fair Value Upside
Unlock7.4%7.1%Unlock

Analyst Ratings

2 Buy
2 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 13.3333
(-6.17% Downside)

Earnings

Latest Release
Aug 06, 2025
EPS / Forecast
-2.27 / -0.09
Revenue / Forecast
-- / 5.00M
EPS Revisions
Last 90 days

MCRB Income Statement

People Also Watch

3.04
SANA
+2.36%
39.385
SMR
-11.85%
4.62
FHTX
-7.23%
9.110
CAPR
+12.89%
46.620
ASTS
-2.28%

FAQ

What Stock Exchange Does Seres Therapeutics Inc Trade On?

Seres Therapeutics Inc is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Seres Therapeutics Inc?

The stock symbol for Seres Therapeutics Inc is "MCRB."

What Is the Seres Therapeutics Inc Market Cap?

As of today, Seres Therapeutics Inc market cap is 124.00M.

What Is Seres Therapeutics Inc's Earnings Per Share (TTM)?

The Seres Therapeutics Inc EPS (TTM) is 10.22.

When Is the Next Seres Therapeutics Inc Earnings Date?

Seres Therapeutics Inc will release its next earnings report on 05 Aug 2025.

From a Technical Analysis Perspective, Is MCRB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Seres Therapeutics Inc Stock Split?

Seres Therapeutics Inc has split 1 times.

How Many Employees Does Seres Therapeutics Inc Have?

Seres Therapeutics Inc has 103 employees.

What is the current trading status of Seres Therapeutics Inc (MCRB)?

As of 08 Aug 2025, Seres Therapeutics Inc (MCRB) is trading at a price of 14.21, with a previous close of 15.29. The stock has fluctuated within a day range of 14.09 to 15.55, while its 52-week range spans from 6.53 to 26.40.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.